Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction.

Trial Profile

Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 May 2014

At a glance

  • Drugs Naproxen sodium/sumatriptan (Primary)
  • Indications Headache
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Apr 2012 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 23 Aug 2010 Additional lead trial investigator (Duren M Ready) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top